Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific executive Stephen Williamson reported tax-related share dispositions. On
After these transactions, Williamson held 32,499.4000 shares of Common Stock directly. He also reported 12,674.0000 shares held indirectly "By SLAT," with a footnote stating he disclaims beneficial ownership of indirectly owned securities except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported three Form 4 transactions on common stock. He disposed of approximately 816 shares through tax-withholding dispositions at a reported price of $521.11 per share to satisfy tax obligations. After these transactions, he directly owns about 22,557 shares of Thermo Fisher Scientific common stock.
Thermo Fisher Scientific Executive Vice President Frederick M. Lowery reported several Form 4 transactions in common stock dated February 28, 2026. He disposed of shares through tax-withholding transactions at $521.11 per share, a method used to cover tax liabilities on equity awards rather than open-market selling. Following these dispositions, he directly held 15,308.3954 shares of common stock. The filing also shows indirect holdings of common stock through a 401(k) plan and a limited liability company. A footnote states he acquired 0.037 shares under the 401(k) plan between February 26 and February 28, 2026, and that he disclaims beneficial ownership of indirectly held securities except for any pecuniary interest.
Thermo Fisher Scientific senior vice president and CFO Stephen Williamson reported an acquisition of 1,534 shares of common stock linked to a performance-based restricted stock unit award granted on February 19, 2025. On February 25, 2026, the Compensation Committee certified that the required performance goals were met.
Following this award, Williamson directly owns 33,421.193 shares of common stock. The filing also notes an indirect holding of 12,674 shares held "By SLAT," for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President & COO Michel Lagarde acquired 2,231 shares of common stock through a performance-based restricted stock unit award. The award was originally granted on February 19, 2025, and the Compensation Committee certified achievement of the performance criteria on February 25, 2026.
The award vests in three equal tranches on February 28, 2026, 2027 and 2028, subject to the terms of the award agreement. Following this grant, Lagarde directly owns 86,347.909 shares of Thermo Fisher Scientific common stock.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported equity awards that increase her direct ownership in the company. She received a grant of stock options for 5,139 shares at an exercise price of $0.00 per option, along with grants of 872 and 1,173 shares of common stock.
The common stock relates to a performance-based restricted stock unit award originally granted on February 19, 2025, for which the compensation committee determined on February 25, 2026, that the performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and 2027, with the remaining third vesting on February 28, 2028 subject to adjustment based on total shareholder return CAGR versus a peer group over the period from January 1, 2025 through December 31, 2027. The option award vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific Executive Vice President Frederick M. Lowery reported an equity award and updated share holdings. He acquired 1,638 shares of common stock through a performance-based restricted stock unit award originally granted on February 19, 2025, after the Compensation Committee certified performance on February 25, 2026. The award is scheduled to vest in three equal tranches on February 28, 2026, 2027, and 2028. A separate performance-based award granted on February 22, 2023 was reduced by 15% based on relative total shareholder return, resulting in 64 fewer shares than previously reported. Between December 2, 2025 and February 26, 2026, he also acquired 10.854 shares of TMO common stock in the company’s 401(k) plan and reports additional indirect holdings through a limited liability company, while disclaiming beneficial ownership of indirectly held shares except for any pecuniary interest.
Thermo Fisher Scientific senior vice president and general counsel Thomas B. Shropshire Jr. reported equity awards on common stock and stock options. He received a grant of stock options for 4,281 shares at an exercise price of
The filing notes that the option grant vests in four equal annual installments beginning on
Shafer Michael D reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported equity awards and adjustments to his holdings. He received a grant of 13,698 stock options and two performance-based stock unit-related common stock awards totaling 4,698 shares.
The filing explains that a performance-based restricted stock unit award granted on February 19, 2025 met its performance criteria on February 25, 2026, with one-third of the shares vesting on February 28, 2026 and 2027, and the final third vesting on February 28, 2028 subject to potential positive or negative adjustment. It also records a 15% reduction to the final tranche of an earlier 2023 performance-based award, resulting in 56 fewer shares than previously reported. The new stock option vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific VP & Chief Accounting Officer Joseph R. Holmes reported equity awards tied to performance-based stock programs. He acquired 985 stock options at an exercise price of
An additional 337 shares of common stock were reported as an adjustment to the final tranche of a 2023 performance-based restricted stock unit award after a 15% reduction in the payout, which resulted in 6 fewer shares than previously reported. The new option grant vests in four equal annual installments beginning on